<PAGE>
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 10-Q/A
AMENDMENT NO. 1
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE SECOND QUARTER ENDED MARCH 31, 1995
COMMISSION FILE NUMBER 1-10492
EPITOPE, INC.
INCORPORATED IN IRS EMPLOYER
THE STATE OF OREGON IDENTIFICATION NO. 93-0779127
8505 S.W. Creekside Place
Beaverton, Oregon 97008-7108
(503) 641-6115
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and (2) has been subject to
such filing requirements for the past 90 days. Yes X No
--- ---
Number of shares of Common Stock, no par value, outstanding as of March 31,
1995: 12,083,706
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Amendment No. 1 to Form 10-Q to be signed on its
behalf by the undersigned thereunto duly authorized.
EPITOPE, INC., an Oregon corporation
May 19, 1995 ADOLPH J. FERRO, PH.D.
- ------------------------ -------------------------------------------------
Date Adolph J. Ferro, Ph.D.
President, Chief Executive Officer and Director
(PRINCIPAL EXECUTIVE OFFICER)
May 19, 1995 GILBERT N. MILLER
- ------------------------ -------------------------------------------------
Date Gilbert N. Miller
Executive Vice President, Chief Financial Officer
(PRINCIPAL FINANCIAL OFFICER)
May 19, 1995 TERRY J. PAULSEN
- ------------------------ -------------------------------------------------
Date Terry J. Paulsen
Accounting Manager
(PRINCIPAL ACCOUNTING OFFICER)
-2-
<PAGE>
EXHIBIT INDEX
Exhibit Description
- ------- -----------
10.1 Development, License and Supply Agreement between Epitope, Inc.
and SmithKline Beecham plc dated February 24, 1995, as amended.
Portions of this agreement are subject to a request for
confidential treatment.
27 Financial Data Schedule
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS CONTAINED IN THE COMPANY'S FORM 10-Q
QUARTERLY REPORT FOR THE FISCAL PERIOD ENDED MARCH 31, 1995, AND IS QUALIFIED
IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> SEP-30-1995
<PERIOD-START> OCT-01-1994
<PERIOD-END> MAR-31-1995
<CASH> 13,345,962
<SECURITIES> 9,063,322
<RECEIVABLES> 514,641
<ALLOWANCES> 45,114
<INVENTORY> 2,357,704
<CURRENT-ASSETS> 25,965,457
<PP&E> 8,719,014
<DEPRECIATION> 4,018,763
<TOTAL-ASSETS> 31,648,452
<CURRENT-LIABILITIES> 2,032,028
<BONDS> 0
<COMMON> 88,191,642
0
0
<OTHER-SE> (62,224,210)
<TOTAL-LIABILITY-AND-EQUITY> 31,648,452
<SALES> 2,787,950
<TOTAL-REVENUES> 2,809,415
<CGS> 3,975,638
<TOTAL-COSTS> 12,291,975
<OTHER-EXPENSES> (347,868)
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (9,134,692)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (9,134,692)
<EPS-PRIMARY> (.80)
<EPS-DILUTED> 0
</TABLE>
